Products
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | 2.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.31 | - |
NAV | ₹31.40 | - |
Fund Started | 20 Jun 2019 | - |
Fund Size | ₹845.30 Cr | - |
Exit Load | Exit load of 1% if redeemed within 30 days. | - |
Risk
Very High
-
Rating
2.0
-
Min SIP Amount
₹100
-
Expense Ratio
2.31
-
NAV
₹31.40
-
Fund Started
20 Jun 2019
-
Fund Size
₹845.30 Cr
-
Exit Load
Exit load of 1% if redeemed within 30 days.
-
Returns
1 Year | -2.85% | - |
3 Year | 23.23% | - |
5 Year | 15.49% | - |
1 Year
-2.85%
-
3 Year
23.23%
-
5 Year
15.49%
-
Holding Analysis
Equity | 97.86% | - |
Cash | 2.14% | - |
Equity
97.86%
-
Cash
2.14%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.96% |
Apollo Hospitals Enterprise Ltd. | 7.65% |
Cipla Ltd. | 7.09% |
Fortis Healthcare Ltd. | 5.15% |
Abbott India Ltd. | 4.82% |
Lupin Ltd. | 4.40% |
Torrent Pharmaceuticals Ltd. | 4.31% |
Ajanta Pharma Ltd. | 3.79% |
Ipca Laboratories Ltd. | 3.61% |
Anthem Biosciences Ltd. | 3.40% |
-
Fund Manager
Name | Dhaval Joshi | - |
Start Date | 21 Nov 2022 | - |
Name
Dhaval Joshi
-
Start Date
21 Nov 2022
-
About Fund
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | - |
Launch Date | 20 Jun 2019 | - |
Description
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
-
Launch Date
20 Jun 2019
-
